Cantargia AB (CANTA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cantargia AB (CANTA) has a cash flow conversion efficiency ratio of 0.943x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr280.72 Million ≈ $30.21 Million USD) by net assets (Skr297.57 Million ≈ $32.02 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cantargia AB - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Cantargia AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Cantargia AB for a breakdown of total debt and financial obligations.
Cantargia AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cantargia AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Frontier Lithium Inc
V:FL
|
0.266x |
|
Icares Medicus Inc
TWO:6612
|
-0.042x |
|
Cibus Global LLC
NASDAQ:CBUS
|
-0.615x |
|
Fulin Plastic Industry Cayman Holding Co Ltd
TW:1341
|
0.123x |
|
Argent
JSE:ART
|
0.099x |
|
Emerging Display Technologies Corp
TW:3038
|
0.078x |
|
Kura Sushi Asia Co Ltd
TWO:2754
|
0.143x |
|
EA Technique M Bhd
KLSE:5259
|
0.067x |
Annual Cash Flow Conversion Efficiency for Cantargia AB (2011–2024)
The table below shows the annual cash flow conversion efficiency of Cantargia AB from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see CANTA company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr116.30 Million ≈ $12.52 Million |
Skr-162.75 Million ≈ $-17.51 Million |
-1.399x | +17.63% |
| 2023-12-31 | Skr168.74 Million ≈ $18.16 Million |
Skr-286.66 Million ≈ $-30.85 Million |
-1.699x | -84.45% |
| 2022-12-31 | Skr389.68 Million ≈ $41.94 Million |
Skr-358.92 Million ≈ $-38.62 Million |
-0.921x | -41.63% |
| 2021-12-31 | Skr532.75 Million ≈ $57.33 Million |
Skr-346.44 Million ≈ $-37.28 Million |
-0.650x | -270.89% |
| 2020-12-31 | Skr891.93 Million ≈ $95.99 Million |
Skr-156.39 Million ≈ $-16.83 Million |
-0.175x | +77.58% |
| 2019-12-31 | Skr142.27 Million ≈ $15.31 Million |
Skr-111.25 Million ≈ $-11.97 Million |
-0.782x | -15.81% |
| 2018-12-31 | Skr155.04 Million ≈ $16.69 Million |
Skr-104.69 Million ≈ $-11.27 Million |
-0.675x | -304.30% |
| 2017-12-31 | Skr246.12 Million ≈ $26.49 Million |
Skr-41.10 Million ≈ $-4.42 Million |
-0.167x | +84.31% |
| 2016-12-31 | Skr37.13 Million ≈ $4.00 Million |
Skr-39.53 Million ≈ $-4.25 Million |
-1.065x | +1.35% |
| 2015-12-31 | Skr28.05 Million ≈ $3.02 Million |
Skr-30.28 Million ≈ $-3.26 Million |
-1.079x | -164.11% |
| 2014-12-31 | Skr4.10 Million ≈ $440.95K |
Skr6.90 Million ≈ $742.32K |
1.683x | +163.81% |
| 2013-12-31 | Skr3.13 Million ≈ $337.02K |
Skr-8.26 Million ≈ $-889.18K |
-2.638x | -114.81% |
| 2012-12-31 | Skr3.08 Million ≈ $331.15K |
Skr-3.78 Million ≈ $-406.73K |
-1.228x | +35.02% |
| 2011-12-31 | Skr1.54 Million ≈ $165.99K |
Skr-2.92 Million ≈ $-313.74K |
-1.890x | -- |
About Cantargia AB
Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an antibody that can bind IL1RAP, which is in phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which… Read more